PARAMUS, N.J., November 4, 2019 – PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer (CSO). This appointment reflects the Company’s growth in Central Nervous System (CNS) drug discovery and clinical development, and its continued commitment to the development of proprietary technologies to support internal and partnered drug discovery and translational research.